Dr. Aseem Malhotra: What 1000s of Doctors Are Saying About The COVID Vaccine Safety Data | TUH #173

Dr. Malhotra explains that metabolic syndrome is the common soil for most chronic diseases. Insulin resistance, driven by high-glycemic carbohydrates and ultra-processed food, causes chronically elevated insulin, which is directly toxic to the endothelium and promotes inflammation. By tracking these five simple markers, individuals can gauge their metabolic health. He notes that even well-controlled type 1 diabetics have a 10-year shorter life expectancy due to exogenous insulin, highlighting insulin's central role. The quickest way to improve these markers is a low-carbohydrate diet, which reduces insulin surges. He emphasizes that this is not about weight loss per se; even slim people can be metabolically unhealthy. The goal is to get all five markers into normal range without medications if possible.

Malhotra argues that the standard dietary advice to eat less fat and more whole grains has failed, as evidenced by the 93% metabolic unhealthiness rate. He points to the success of low-carb interventions in rapidly improving triglycerides, HDL, and blood pressure. He references the lean mass hyper-responder study to reassure that even very high LDL on a low-carb diet is not associated with plaque progression. He emphasizes that the diet must be whole-food based, not simply low-carb junk food. The goal is to keep insulin low, which also benefits mental health (as explored by Stanford's metabolic psychiatry unit) and reduces cancer risk. He notes that this approach is not taught in medical school, so patients must self-educate or find knowledgeable practitioners.

Malhotra argues that the food environment is the primary driver of the chronic disease epidemic. 60% of U.S. calories come from ultra-processed foods. These products are engineered to be hyper-palatable and addictive, and they are marketed aggressively, often targeting children and vulnerable populations. He points out that even hospitals sell them, which legitimizes their consumption. He advises patients that if a food is advertised as healthy, it's likely the opposite. The solution requires both individual avoidance and policy change, such as banning sales in schools and hospitals and restricting advertising. He draws parallels to tobacco control, which succeeded through taxation, public education, and environmental restrictions.

Malhotra acknowledges that many people are worried about vaccine injury and that protocols like Peter McCullough's exist. He says, 'If it's going to potentially do you some good and no harm, why not?' but stresses that the evidence is still limited. He mentions that some companies claim NAC and nattokinase can denature spike protein, but these claims may be biased. He emphasizes that the most important step is to improve metabolic health, as those with poor metabolic health are more likely to suffer complications from the vaccine. He also notes the psychological trauma of being vaccine-injured and the need for psychological support. He does not endorse a specific protocol but suggests a cautious, individualized approach.

The reanalysis revealed that the rate of serious harm (life-changing event, disability, or hospitalization) was 1 in 800, while the rate of hospitalization with COVID in the trial was less than 1 in 800. This means the vaccine was more harmful than beneficial even in the short term for a relatively healthy population. Dr. Malhotra emphasizes that this is likely an underestimate because those with comorbidities were more susceptible to adverse events. He contrasts this with historical vaccine withdrawals: the 1976 swine flu vaccine was pulled at a harm rate of 1 in 100,000 for Guillain-Barré syndrome, and the 1999 rotavirus vaccine was suspended at 1 in 10,000 for bowel obstruction. The fact that the COVID vaccine remained on the market with a harm rate orders of magnitude higher reveals a profound regulatory failure. The paper was published in Vaccine, a top-tier journal, yet received no mainstream press coverage until Dr. Malhotra and others amplified it through alternative media. He recounts meeting Richard Horton, editor of The Lancet, who was unaware of the publication and called it “a pretty credible journal” but said nothing further. This silence, Malhotra argues, is emblematic of the corporate capture of medicine and media.

Malhotra argues that the COVID vaccine scandal is the culmination of decades of unchecked corporate power. He points out that the very name 'Operation Warp Speed' signaled a willingness to sacrifice safety for speed, as fast-tracked drugs have a higher withdrawal rate. The regulators tasked with protecting the public are funded by the industry they oversee: 86% of the UK's Medicines and Healthcare products Regulatory Agency (MHRA) budget comes from pharma, and 65% of the FDA's. This conflict of interest, he says, is why the 1 in 800 harm signal was ignored. He also details how Pfizer lobbied grassroots organizations in the summer of 2021 to push vaccine mandates, a tactic to distract from emerging real-world harm data and to imply that mandated products must be safe. This corporate influence extends to the cholesterol hypothesis: a trillion-dollar industry depends on the fear of LDL, and new expensive drugs are being pushed despite evidence that lowering LDL does not linearly reduce heart attacks. Malhotra calls this 'corporate tyranny'—a system where doctors are afraid to speak out, and where the medical establishment has lost public trust, with trust in doctors dropping from 74% in April 2020 to about 40%.

Malhotra systematically dismantles the cholesterol hypothesis. He starts by noting cholesterol's vital roles in hormone production, cell membranes, and immunity. The fear of cholesterol arose from the Framingham study, but Castelli's 1996 reanalysis found that only LDL above 300 mg/dL—essentially familial hyperlipidemia (FH)—predicted heart disease. Even in FH, 70% of women and 50% of men do not develop premature heart disease; the real predictors are lipoprotein(a), fibrinogen, and metabolic abnormalities. Malhotra's own 2016 BMJ Open study of over 70,000 participants found no association between LDL and heart disease in people over 60, and an inverse association with all-cause mortality (higher LDL, lower death risk), likely due to LDL's role in immune function. A 2020 systematic review of 35 RCTs found no relationship between the degree of LDL lowering and cardiovascular benefit. Statins do show a small benefit, but Malhotra argues this is due to their anti-inflammatory and anti-clotting effects, not cholesterol reduction. He cites the recent lean mass hyper-responders study using Cleerly CCTA: 100 people with LDL over 200 mg/dL (some up to 500) on a keto diet showed no plaque progression over one year, and no relationship between LDL and plaque. Consequently, Malhotra tells patients that lowering LDL is not part of his management plan.